# US 2020/0261501 A1 · Anti-bcma car t cell compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0261501 A1
- Document ID: US20200261501A1
- Status: Published application
- Kind: A1
- Application number: 16/346,393
- Filed: 2017-11-03
- Published: 2020-08-20
- Earliest claimed: 2016-11-04
- Assignees: bluebird bio, Inc.
- Applicants: bluebird bio, Inc.
- Inventors: Travis QUIGLEY; Robert ROSS
- Web page: https://patentgrep.com/patent/US20200261501A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A01K 67/0271: Chimeric vertebrates, e.g. comprising exogenous cells
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- C12N 2740/10041: Use of virus, viral particle or viral elements as a vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides improved anti-BCMA CAR T cell compositions for adoptive T cell therapy for relapsed/refractory multiple myeloma.

## Claims

### Claim 1

A composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells, wherein the therapeutically effective amount is at least about 15.0×107 anti-BCMA CAR T cells, and the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO: 9.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The composition of claim 1, formulated in a solution comprising 50:50 PlasmaLyte A to CryoStor CS10.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The composition of claim 1, wherein the therapeutically effect amount is:
(a) at least about 45.0×107 anti-BCMA CAR T cells;
(b) at least about 80.0×107 anti-BCMA CAR T cells; or
(c) at least about 12.0×108 anti-BCMA CAR T cells.

### Claim at position 6

-11. (canceled)

### Claim 12 (depends on 1)

The composition of claim 1, wherein the therapeutically effect amount is:
(a) between about 15.0×107 anti-BCMA CAR T cells and about 45.0×107 anti-BCMA CAR T cells;
(b) between about 15.0×107 anti-BCMA CAR T cells and about 80.0×107 anti-BCMA CAR T cells; or
(c) between about 15.0×107 anti-BCMA CAR T cells and about 12.0×108 anti-BCMA CAR T cells.

### Claim at position 8

-14. (canceled)

### Claim 15 (depends on 1)

The composition of claim 1, wherein the anti-BCMA CAR T cells are transduced with a lentiviral vector encoding the anti-BCMA CAR.

### Claim 16

(canceled)

### Claim 17 (depends on 15)

The composition of claim 15, wherein the lentiviral vector is a human immunodeficiency virus 1 (HIV-1) vector.

### Claim 18

A pharmaceutical composition comprising a population of T cells transduced with a lentivirus encoding an anti-BCMA CAR, wherein population of T cells comprises at least about 15.0×107 anti-BCMA CAR T cells, and the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO: 9.

### Claim at position 13

-20. (canceled)

### Claim 21 (depends on 18)

The pharmaceutical composition of claim 18, wherein the composition comprises:
(a) at least about 45.0×107 anti-BCMA CAR T cells;
(b) at least about 80.0×107 anti-BCMA CAR T cells; or
(c) at least about 12.0×108 anti-BCMA CAR T cells.

### Claim at position 15

-27. (canceled)

### Claim 28 (depends on 18)

The pharmaceutical composition of claim 18, wherein the composition comprises:
(a) between about 15.0×107 anti-BCMA CAR T cells and about 45.0×107 anti-BCMA CAR T cells;
(b) between about 15.0×107 anti-BCMA CAR T cells and about 80.0×107 anti-BCMA CAR T cells; or
(c) between about 15.0×107 anti-BCMA CAR T cells and about 12.0×108 anti-BCMA CAR T cells.

### Claim at position 17

-30. (canceled)

### Claim 31 (depends on 18)

The pharmaceutical composition of claim 18, wherein the T cells comprise CD8+ T cells.

### Claim 32

(canceled)

### Claim 33 (depends on 18)

A method of treating a subject that has relapsed/refractory multiple myeloma comprising administering to the subject the pharmaceutical composition of claim 18.

### Claim 34 (depends on 33)

The method of claim 33, wherein the pharmaceutical composition is administered in a single dose.

### Claim 35 (depends on 33)

The method of claim 33, wherein the pharmaceutical composition is intravenously administered.

### Claim 36 (depends on 33)

The method of claim 33, wherein the multiple myeloma was refractory to at least three treatment regimens, including treatment with a proteasome inhibitor and treatment with an immunomodulatory agent, prior to the administration of the pharmaceutical composition.

### Claim 37 (depends on 33)

The method of claim 33, where the multiple myeloma was double-refractory to one or more treatment regimens, prior to the administration of the composition.

### Claim 38 (depends on 33)

The method of claim 33, wherein the subject was treated with daratumumab, lenalidomide, pomalidomide, bortezomib, and/or carfilzomib, prior to the administration of the composition.

### Claim 39 (depends on 33)

The method of claim 33, wherein the subject received an autologous hematopoietic stem cell transplant, prior to the administration of the composition.

### Claim 40 (depends on 33)

The method of claim 33, wherein the subject was lymphodepleted with cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2.
